Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $26.
August 17, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Silence Therapeutics, maintaining a price target of $26.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Silence Therapeutics. The maintained price target of $26 suggests that the analyst believes the stock has potential for growth, which could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100